A clinical-stage company focusing on immuno-oncology and autoimmune conditions with therapies that modulate T cell responses.

Georgiamune is developing novel immune checkpoint blockades to address the needs of cancer patients that do not benefit from first-generation checkpoint inhibitors, such as Merck's Keytruda.  Additionally, Georgiamune is developing oral small molecule specific regulatory T cell activators and inhibitors that address the underlying pathology that drives the progression of various cancers and/or autoimmune disorders.